SCHEMBL12174379

SCHEMBL12174379

COc1ccc(-c2ccccc2C(=O)Nc2ccc(N3CCC(C(C(=O)Nc4ccccc4)c4ccccc4)CC3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 6/20 0.58
▸ GAA P10253 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ MTTP P55157 3/20 0.54
▸ KDM4E B2RXH2 2/20 0.48
▸ MAPT P10636 6/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HTR1E P28566 2/20 0.47
▸ S1PR3 Q99500 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ AHR P35869 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ FPR2 P25090 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MCL1 Q07820 2/20 0.46
▸ NR4A1 P22736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12174405 0.92 NPY2R (0.65) NPY2RGAAPOLBMTTPKDM4E
SCHEMBL12174185 0.91 NPY2R (0.57) NPY2RGAAPOLBMTTPKDM4E
SCHEMBL12174398 0.91 NPY2R (0.61) NPY2RGAAPOLBMTTPKDM4E
SCHEMBL12174481 0.90 HTR1E (0.59) NPY2RGAAMTTPMAPTKMT2A
SCHEMBL12174499 0.88 NPY2R (0.59) NPY2RMTTPMAPTKMT2ALMNA
SCHEMBL12174526 0.88 NPY2R (0.54) NPY2RGAAMTTPKDM4EMAPT
SCHEMBL12174523 0.86 KMT2A (0.55) NPY2RGAAPOLBMTTPKDM4E
SCHEMBL12174402 0.86 MTTP (0.54) NPY2RGAAMTTPKDM4EMAPT
SCHEMBL12157835 0.85 NPY2R (0.72) NPY2RGAAPOLBMTTPMAPT
SCHEMBL12174462 0.84 MAPT (0.53) NPY2RGAAPOLBMTTPKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354402-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-15 — — US disclosed
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2011-11-03 — — US disclosed
EP-1317431-B1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS JANSSEN PHARMACEUTICA NV (BE) 2010-10-20 — — EP disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 — — US disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 — — US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 — — US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 — — US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 — — US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 — — US disclosed
EP-1806341-A2 (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 — — EP disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 — — US disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 — — US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 — — US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB NPY2R 4187/4885GAA 476/4885POLB 2420/4885
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB NPY2R 4187/4885GAA 476/4885POLB 2420/4885
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB NPY2R 4187/4885GAA 476/4885POLB 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback